A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Eligible age
18–75 yrs
Accepts
All genders
Locations
33 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The study will assess the efficacy and safety of pegozafermin administered in participants with compensated cirrhosis due to MASH (biopsy-confirmed fibrosis stage F4 MASH \[previously known as nonalcoholic steatohepatitis, NASH\]).
Sponsor: 89bio, Inc.
Where it's recruiting
Birmingham · Homewood
Chandler · Flagstaff · Peoria · Phoenix …
Little Rock · North Little Rock
Camarillo · Canoga Park · Coronado · Fountain Valley …
Littleton
Clermont · Fort Myers · Gainesville · Hialeah Gardens …
Athens · Atlanta
Chicago
Hammond · New Albany · South Bend
Iowa City
Kansas City · Topeka
Lafayette · Lake Charles · West Monroe
Source: ClinicalTrials.gov · NCT06419374 · last updated 2026-06-04